劉華 靳永亮 張紀越 朱伶俐 盛天露 劉峰
摘?要:毛梗豨薟草(Siegesbeckia glabresce)的乙酸乙酯萃取部位具有顯著的抑制細胞壞死性凋亡(necroptosis)的活性。為明確毛梗豨薟草的活性成分,該研究采用正相硅膠柱色譜譜(二氯甲烷∶甲醇20∶1~0∶1)、反相ODS柱色譜(30%~100% 甲醇)、Sephadex LH-20柱色譜、重結晶等方法對毛梗豨薟草乙酸乙酯萃取部位進行了化學成分分離和純化,并根據(jù)理化性質和波譜數(shù)據(jù)進行了結構鑒定。結果表明:從毛梗豨薟乙酸乙酯部位分離并鑒定了9個化合物,分別為3,7-二甲氧基槲皮素(1)、芹菜素(2)、奧卡寧(3)、okanin-4′-O-β-D-6″-trans-p-coumaroylglucoside(4)、1H-Indole-3-carbaldehyde(5)、對羥基苯甲醛(6)、3,5-二甲氧基-4-羥基苯甲醛(7)、3,4-divanillyltetrahydrofuran(8)、buddlenol D(9)。除化合物1和化合物6外,其余7個化合物均為首次從豨薟屬植物中分離得到。
關鍵詞:毛梗豨薟草, 乙酸乙酯部位, 提取分離, 化學成分, 生物活性
中圖分類號:Q946
文獻標識碼:A
文章編號:1000-3142(2020)12-1699-07
Abstract:The ethyl acetate extracts of Siegesbeckia glabrescens had significant physiological activity to inhibit necroptosis. In order to identify the active components and find the target compounds, the ethyl acetate extracts of S. glabresce were isolated and studied systemically in chemistry. The compounds were isolated and purified by chroma-tography on silica gel, ODS, and Sephadex LH-20 columns, and their structures were determined according to physicochemical properties and spectral analyses. Nine compounds were isolated from the ethyl acetate of S. glabresce and identified as 3,7-dimethoxyquencetin(1), apigenin(2), okanin(3), okanin-4′-O-β-D-6″-trans-p-coumaroylglucoside(4), 1H-indole-3-carbaldehyde(5), p-hydroxybenzaldehyde (6), 3,5-dimethoxy-4-hydroxybenzaldehyd (7), 3,4-divanillyltetrahydrofuran(8), buddlenol D(9). Compounds 2-5, 7-9 were isolated in this herbal plant for the first time.
Key words:?Siegesbeckia glabresce, ethyl acetate extracts, extraction and separation, chemical components, bioactivity
中藥豨薟草為菊科豨薟屬一年生草本植物豨薟(Siegesbeckia orientalis)、腺梗豨薟(S. pubescens)和毛梗豨薟(S. glabrescens)的干燥地上部分(中華人民共和國藥典·一部,2015),性寒,味辛、苦,歸肝、腎經(jīng),可利關節(jié)、通經(jīng)絡。目前,對豨薟草藥理研究表明,豨薟草在抗炎(Hong et al., 2014;Nguyen et al., 2017;朱伶俐等,2018) 、抗風濕(傅旭春等,2013;Wu et al., 2017)、抗腫瘤(Lu et al., 2014;Lee et al., 2014;Chang et al., 2016)、抗菌(Kim et al., 2016;陳少紅等, 2017)、抗氧化(Park et al., 2013;Zhang et al., 2014)和心血管保護(Weber et al., 2007;王發(fā)輝等, 2012)等方面效用良好,活性成分集中于二萜類(Yang et a., 2016)、倍半萜類(Wu et al., 2015;Lee et al., 2016)、黃酮類(婁月芬等,2013)等化合物。
細胞壞死性凋亡 (necroptosis)是近年來新發(fā)現(xiàn)的一種具有程序性可調控的非半胱氨酸蛋白酶(caspase) 依賴的、通過死亡受體誘導的一種細胞死亡類型。主要由腫瘤壞死因子受體( tumor necrosis factor, TNF-α) 家族以及Toll 樣受體(Toll-like receptors,TLR)家族啟動,通過兩個蛋白激酶RIPK1(receptor interacting protein kinase 1)和RIPK3(receptor interacting protein kinase 3)傳遞死亡信號,募集并磷酸化MLKL (mixed lineage kinase domain-like protein) (吳晨露等,2016),執(zhí)行細胞死亡,細胞發(fā)生壞死。細胞壞死性凋亡是許多疾病惡化的根源,可能在包括癌癥、代謝疾病、神經(jīng)退行性病癥以及心肌梗死、中風、胰腺炎、腸炎和皮膚炎等疾病的發(fā)病機制中起到重要作用(Andreas & Green, 2014;Dongshi et al., 2016)。
本課題組前期自建了江西100種中草藥提取物組分庫,并對樣品進行篩選,發(fā)現(xiàn)毛梗豨薟草的95% 醇提物浸膏乙酸乙酯萃取部位和二氯甲烷部位具有很強的抑制necroptosis的活性。為明確毛梗豨薟草的活性成分,對活性部位通過硅膠柱色譜、ODS 柱色譜、凝膠柱色譜、HPLC 等方法進行了化學成分分離,從乙酸乙酯部位分離得到9個化合物,分別為3,7-二甲氧基槲皮素(1)、芹菜素(2)、奧卡寧(3)、okanin-4′-O-β-D-6″-trans-p-coumaroylglucoside(4)、1H-indole-3-carbaldehyde(5)、對羥基苯甲醛(6),3,5-二甲氧基-4-羥基苯甲醛(7)、3,4-divanillyltetrahydrofuran(8)、buddlenol D(9)。除化合物1和化合物6外,其余7個化合物均為首次從豨薟屬植物中分離得到。
1?材料與方法
1.1 材料、儀器和試劑
1.1.1 材料?藥材于2015年5月購于江西樟樹,由江西中醫(yī)藥大學賴學文教授鑒定為菊科植物豨薟屬毛梗豨薟(Siegesbeckia glabresce),憑證標本保存于江西中醫(yī)藥大學標本室,編號為ZY-20150525。
活性篩選用的細胞系為人直腸癌細胞系HT29,培養(yǎng)基為DMEM Medium加10%FBS和1%P/S。
1.1.2 儀器和試劑?儀器:2695 Alliance Separations Module型高效液相色譜儀和1525型制備高效液相色譜儀[LichrospherC18制備液相色譜柱( 30 mm × 250 mm,10 μm)](美國Waters 公司);Inova-600 型超導核磁共振波譜儀(美國Varian公司);WFH-203 (ZF-1)型三用紫外分析儀(上海精科實業(yè)有限公司);AE100型電子分析天平(瑞士梅特勒-托利多公司)。試劑:LH-20羥丙基葡聚糖凝膠( Sephadex LH-20,瑞典GE Healthcar公司);柱色譜及薄層色譜用硅膠(200目,青島海洋化工廠產品);ODS柱色譜填料(50 μm,日本YMC公司);提取分離用試劑均為分析純,制備HPLC 用甲醇為色譜純(西隴化工股份有限公司);水為三蒸水。
Cell Titer-Glo細胞活性檢測試劑盒購于Promega公司,腫瘤壞死因子TNF-α通過大腸桿菌表達系統(tǒng)表達并純化得到;促凋亡化合物Smac mimetic 和Caspase 抑制劑z-VAD.fmk由北京生命科學研究所化學中心合成。
1.2 方法
1.2.1 提取與分離?取干燥毛梗豨薟全草25 kg,粉碎后用95%乙醇回流提取4次,每次3 h。合并提取液,減壓回收溶劑得總浸膏1.2 kg。加蒸餾水混懸,依次用石油醚、乙酸乙酯、正丁醇萃取,得到五個萃取部位,分別取各組分浸膏20 mg用DMSO配制成20 mg·mL-1儲存液,編號,于-20 ℃保存,備篩選用。
1.2.2 Cell Titer-Glo細胞活性檢測方法?三磷酸腺苷(Adenosine Tri-Phosphate, ATP)是活性細胞新陳代謝的一個指標。CTG法是通過Cell Titer-GloTM活細胞檢測試劑盒螢光素酶的熒光發(fā)光值反映出ATP含量的高低,直接反映細胞的數(shù)量及細胞狀態(tài),非常適合高通量篩選、細胞增殖和細胞毒性分析。
1.2.3 活性篩選?HT29(人直腸癌)細胞模型,首先經(jīng)TSZ(終濃度分別為20 ng·mL-1TNF-α、100 nmol·mL-1 Smac和 20 nmol·mL-1 z-VAD誘導過夜后,產生necroptosis。然后,將配成20 mg·mL-1的樣品加入到經(jīng)TSZ處理誘導成細胞壞死的HT29細胞模型中,37 ℃恒溫培養(yǎng)箱放置過夜。最后,用Cell Titer-Glo(Promega)試劑盒檢測細胞ATP水平以確定細胞存活率。細胞存活率高的組分,說明對TSZ介導的細胞壞死有抑制作用。
2?結果與分析
2.1 活性部位篩選結果
將DMSO配成的5份儲存液編號為A(總浸膏)、B(石油醚萃取部位)、C(乙酸乙酯萃取部位)、D(正丁醇萃取部位)和E(水部位)。篩選結果如圖1所示。
由圖1可知,經(jīng)TSZ誘導的HT29細胞的存活率僅有9%,誘導成necroptosis的HT29細胞在加入B(石油醚萃取部位)、D(正丁醇萃取部位)和E(水部位)配成的樣品后的存活率并未得到改善。但是,A(總浸膏)已將存活率提高到45%,C(乙酸乙酯萃取部位)的存活率高達77%,遠高于未加樣品的9%的存活率。這個結果說明毛梗豨薟對necroptosis有抑制作用,而乙酸乙酯萃取部位為其活性部位。
2.2 活性部位化學分離結果
取活性組分乙酸乙酯萃取部位浸膏(60 g),加水混懸后,與100 g的100~200目硅膠干法上柱,依次以石油醚∶乙酸乙酯15∶1~0∶1梯度洗脫。洗脫后的流份經(jīng)TLC合并,得到Fr-a~Fr-j等10個組分。各組分分別以開放型ODS柱色譜法進行分離,得到的各流份經(jīng)TLC合并相同組分。其中,F(xiàn)r-b-2經(jīng)制備型高壓柱色譜進行分離,以30%甲醇等度洗脫,得到化合物3(10 mg)。Fr-d-2經(jīng)制備型高壓柱色譜以30%甲醇等度洗脫,得到化合物2(7 mg)。Fr-d-3、Fr-d-4先經(jīng)Sephadex LH-20純化后,再經(jīng)制備型高壓柱色譜分別以50%甲醇、40%甲醇等度洗脫,得到化合物4(7 mg)、化合物5(6 mg)和化合物8(15 mg)。Fr-e-3先經(jīng)制備型高壓柱色譜以50%甲醇等度洗脫,得到化合物1(5 mg)。Fr-f-5經(jīng)制備型高壓柱色譜以45%甲醇等度洗脫,得到化合物9(6 mg)。Fr-h-2、Fr-h-3先經(jīng)Sephadex LH-20純化后,再經(jīng)制備型高壓柱色譜分別以55%甲醇、50%甲醇等度洗脫,得到化合物6(8 mg)和7(5 mg)。
從乙酸乙酯部位分離得到的9個化合物,分別為4個黃酮類化合物,即3,7-二甲氧基槲皮素(1)、芹菜素(2)、奧卡寧(3)、okanin-4′-O-β-D-6″-trans-p-coumaroylglucoside(4);1個生物堿類化合物,即1H-indole-3-carbaldehyde(5);2個芳香化合物,即對羥基苯甲醛(6)和3,5-二甲氧基-4-羥基苯甲醛(7);2個木脂素類化合物,即3,4-divanillyltetrahydrofuran(8)和buddlenol D(9)。除化合物1和化合物6外,其余7個化合物均為首次從豨薟屬植物中分離得到。
化合物1?黃色針晶(甲醇)。HR-ESI-MS m/z: 329.0740[M-H]-,分子式為C17H14O7。1H-NMR(CD3OD,600 MHz)δ:7.67(1H,d,J=2.1 Hz,H-2′),7.56(1H,dd,J=8.5 Hz,J=2.1 Hz,H-6′),6.91(1H,d,J=8.5 Hz,H-5′),6.59(1H,d,J=2.1 Hz,H-8),6.33(1H,d,J=2.1 Hz,H-6),3.89(3H,s,3-OCH3),3.80(3H,s,7-OCH3)。13C-NMR(CD3OD,150 MHz)δ:148.7(C-2,4′),138.3(C-3),178.7(C-4),156.9(C-5),97.5(C-6),165.9(C-7),91.7(C-8),161.5(C-9),105.3(C-10),121.4(C-1′),115.2(C-2′),145.1(C-3′),115.0(C-5′),121.0(C-6′),59.1(C-3-OCH3),55.1(C-7-OCH3)。以上數(shù)據(jù)與文獻(Xiong et al., 1997) 報道一致,故鑒定化合物為3, 7-二甲氧基槲皮素(3, 7-dimethoxyquercetin)。
化合物2?淡黃色針狀結晶(甲醇)。HR-ESI-MS m/z:270.9702[M+H]+,分子式為C15H10O5。1H-NMR(DMSO-d6 ,600 MHz)δ:12.97(1H,s,5-OH),10.92(1H,s,7-OH),10.42(1H,s,4′-OH),7.93(2H,d,J=8.3 Hz,H-2′,H-6′),6.97(2H,d,J=8.4 Hz,H-3′,H-5′),6.79(1H,s,H-3),6.50(1H,d,J=2.1 Hz,H-6),6.20(1H,d,J=2.1 Hz,H-8)。13C-NMR(DMSO-d6,150 MHz)δ:164.6(C-2),103.3(C-3),182.2(C-4),157.7(C-5),99.3(C-6),164.2(C-7),94.4(C-8),161.9(C-9),104.1(C-10),121.6(C-1′),130.1(C-2′),116.4(C-3′),161.7(C-4′),116.4(C-5′),128.9(C-6′)。 以上數(shù)據(jù)與文獻(李曉亮等,2007)報道一致,故鑒定化合物為芹菜素(apigenin)。
化合物3?紅棕色粉末(甲醇)。HR-ESI-MS m/z:287.0556[M-H]-,分子式為C15H12O6。1H-NMR(DMSO-d6,600 MHz)δ:7.25(1H,d,J=1.8 Hz,H-2),7.18(1H,dd,J=8.4 Hz,J=1.8 Hz,H-5),6.80(1H,d,J= 8.4 Hz,H-6),7.63(1H, d,J=15.6 Hz,H-α),7.65(1H,d,J= 15.6 Hz,H-β),6.41(1H,d,J=9.0 Hz,H-5′),7.67(1H,d,J=9.0 Hz,H-6′)。13C-NMR(DMSO-d6,150 MHz)δ:126.3(C-1),115.9(C-2),145.6(C-3),148.9(C-4),115.8(C-5),122.3(C-6),122.3(C-α),144.6(C-β),192.0(C=O),113.4(C-1′),153.6(C-2′),132.4(C-3′),152.5(C-4′),107.7(C-5′),117.4(C-6′)。以上數(shù)據(jù)與文獻(Kwon et al., 2009)報道一致,故鑒定化合物為奧卡寧(okanin)。
化合物4?黃色粉末(甲醇),Molish反應陽性。1H-NMR(DMSO-d6,600 MHz)δ:7.27(1H,d,J=1.8 Hz,H-2),7.21(1H,dd,J=8.4 Hz,J=1.8 Hz,H-5),6.84(1H,d,J=8.4 Hz,H-6),7.65(1H,d,J=15.6 Hz,H-α),7.69(1H,d,J=15.6 Hz,H-β),6.75(1H,d,J=9.0 Hz,H-5′),7.75(1H,d,J=9.0 Hz,H-6′),δ:3.75~5.47為葡萄糖上質子信號,7.56(2H,d,J=9.0 Hz,H-2,H-6),6.73(2H,d,J=9.0 Hz,H-3,H-5),6.43(1H,d,J=16.2 Hz,H-8),7.55(1H,d,J=16.2 Hz,H-9)。13C-NMR(DMSO-d6 ,150 MHz)δ:126.1(C-1),116.2(C-2),145.6(C-3),149.1(C-4),115.5(C-5),122.2(C-6),117.4(C-α),145.4(C-β),192.6(C=O),115.7(C-1′),152.5(C-2′),134.4(C-3′),150.3(C-4′),106.3(C-5′),121.4(C-6′),100.5(C-1″),73.8(C-2″),75.7(C-3″),69.9(C-4″),73.1(C-5″),63.3(C-6″),125.0(C-1),130.4(C-2,C-6),115.7(C-3,C-5),159.9.(C-4),145.0(C-7),113.9(C-8),166.5(C-9)。以上數(shù)據(jù)與文獻(Hoffmann & Hlzl, 1988)報道一致,故鑒定化合物為okanin-4′-O-β-D-6″-trans-p-coumaroylglucoside。
化合物5?白色針晶(甲醇)。HR-ESI-MS m/z:146.0602[M+H]+,分子式為C9H7NO。1H-NMR(CD3OD,600 MHz)δ:9.90(1H,s,3a-CHO),8.18(1H,dt,J=7.7 Hz,J=1.1 Hz,H-4),8.10(1H,s,H-2),7.27(1H,m,H-5),7.27(1H,m,H-6),7.49(1H,dt,J=8.1 Hz,J=1.0 Hz,H-7)。13C-NMR(CD3OD,150 MHz)δ:138.3(C-2),118.7(C-3),124.3(C-3′),122.2(C-4),121.0(C-5),123.6(C-6),111.7(C-7),137.5(C-7′),186.0(C-3a)。以上數(shù)據(jù)與文獻(Yang & Ye, 2009)報道一致,故鑒定化合物為1H-indole-3-carbaldehyde。
化合物6?淡黃色粉末(甲醇)。HR-ESI-MS m/z:123.0441[M+H]+,分子式為C7H6O2。1H-NMR(CD3OD,600 MHz)δ:9.72(1H,s,-CHO),7.76(2H,d,J=8.7 Hz,H-3/5),6.87(2H,d,J=8.6 Hz,H-2/6)。13C-NMR(CD3OD,150 MHz)δ:127.6(C-1),132.2(C-2/6),116.3(C-3/5),166.5(C-4),191.2(-CHO)。以上數(shù)據(jù)與文獻(方前波等,2010)報道一致,故鑒定化合物為對羥基苯甲醛(p-hydroxybenzaldehyde)。
化合物7?淡黃色固體(甲醇)。HR-ESI-MS m/z:183.0645[M+H]+,分子式為C9H10O4。1H-NMR(CD3OD,600 MHz)δ:9.74(1H,s,-CHO),7.21(2H,s,H-2/6),3.93(6H,s,-OCH3)。13C-NMR(CD3OD,150 MHz)δ:106.9(C-2/6),148.5(C-3/5),191.4(-CHO),55.4(-2*OCH3)。以上數(shù)據(jù)與文獻(Chang et al., 2013)報道一致,故鑒定化合物為3,5-二甲氧基-4-羥基苯甲醛(3,5-dimethoxy-4-hydroxybenzaldehyde)。
化合物8?無色針狀晶體(甲醇)。HR-ESI-MS m/z:343.1545[M-H]-,分子式為C20H24O5。1H-NMR(CD3OD,600 MHz)δ:6.59(2H,d,J=2.0 Hz,H-3/3′),6.67(2H,d,J=7.9 Hz,H-6/6′),6.53(2H,dd,J=8.0 Hz,J=2.0 Hz,H-5/5′),3.87(2H,dd,J=8.6 Hz,J=6.6 Hz,H-9/9′a),3.78(6H,s,2/2′-OMe),3.50(2H,dd,J=8.6 Hz,J=6.6 Hz,H-9/9′b),2.51(4H,dd,J=7.2Hz,J=5.3 Hz,H-7/7′),2.18(2H,m,H-8/8′)。13C-NMR(CD3OD,150 MHz)δ:144.4(C-1/1′),147.5(C-2/2′),111.9(C-3/3′),131.9(C-4/4′),120.8(C-5/5′),114.6(C-6/6′),38.5(C-7/7′),46.3(C-8/8′),73.0(C-9/9′),54.9(2/2′-OMe)。以上數(shù)據(jù)與文獻(Lai-King & Brown, 1998)報道一致,故鑒定化合物為3,4-divanillyltetrahydrofuran。
化合物9?淡黃色固體(甲醇)。HR-ESI-MS m/z:643.1002[M-H]-,分子式為C33H40O13。1H-NMR(CD3OD,600 MHz)δ:6.69(2H,s,H-2/6),6.66(2H,s,H-2″/6″),6.28(2H,s,H-2′/6′),4.99(1H,m,H-7″),4.77(1H,d,J=4.5 Hz,H-7),4.74(1H,d,J=4.5 Hz,H-7′),4.31(1H,m,H-9a),4.31(1H,m,H-9′a),4.31(1H,m,H-8″),3.93(1H,m,H-9′b),3.93(1H,m,H-9b),3.93(1H,m,H-9″a),3.93(1H,dd,J=12.0 Hz,J=3.5 Hz,H-9″b),3.87(6H,s,2*OMe),3.84(6H,s,2*OMe),3.83(6H,s,2*OMe),3.16(1H,m,H-8),3.16(1H,m,H-8′)。13C-NMR(CD3OD,150 MHz)δ:134.8(C-1),102.8(C-2/6),147.5(C-3/5),137.5(C-4),85.9(C-7),54.3(C-8),71.5(C-9),134.8(C-1′),103.1(C-2′/6′),153.1(C-3′/5′),131.7(C-4′),85.7(C-7′),54.0(C-8′),71.6(C-9′),131.6(C-1″),103.8(C-2″/6″),147.9(C-3″/5″),134.4(C-4″),72.9(C-7″),86.2(C-8″),60.4(C-9 ″),55.4(2*OMe),55.3(2*OMe),55.3(2*OMe)。以上數(shù)據(jù)與文獻(鐘金棟等,2013)報道一致,故鑒定化合物為buddlenol D。
3?討論
豨薟草為我國傳統(tǒng)中草藥,臨床應用廣泛,多以復方有效治療痛風、類風濕性關節(jié)炎、三叉神經(jīng)痛、高血壓、冠心病、黃疸型肝炎、中風及其后遺癥等(沈震等,2013;石斌豪等,2015;王遠征和李國慶,2016;劉流,2016;Liu et al., 2016; 盧裕強等,2016;何威和曹亞麗,2016)。化學成分以黃酮類、二萜和倍半萜類化合物居多。本課題組前期研究發(fā)現(xiàn),毛梗豨薟草具有很強的抑制細胞壞死性凋亡(necroptosis)的活性,并對其進行了化學成分分離,得到的9個化合物,除化合物1和化合物6外,其余 7個化合物均為首次從豨薟屬植物中分離得到。
最新的研究表明,necroptosis在許多疾病的發(fā)病機制中起到重要作用,抑制necroptosis能減少這些疾病帶來的損傷。因此,necroptosis代表了一類廣泛疾病的治療目標,尋找特異性抑制劑來調控necroptosis,在生物醫(yī)學研究和創(chuàng)新藥物研發(fā)領域都具有至關重要的意義,可以為治療多種疾病提供新的思路,這已成為當今新藥研究的熱點。
本研究豐富了豨薟草的化學成分,為下一步發(fā)現(xiàn)豨薟草細胞壞死性凋亡抑制劑提供了化學依據(jù),也為設計開發(fā)針對細胞壞死性凋亡相關疾病的臨床藥物奠定了一定的化學基礎,同時對豐富的豨薟草野生資源的開發(fā)和利用起到一定的推動作用。
參考文獻:
ANDREAS L, DAUGLAS R, GREEN, 2014. Necroptosis[J]. N Engl J Med, 1:455-465.
CHANG CC, LING XH, HSU HF, et al.,2016. Siegesbeckia orientalis extract inhibits TGFβ1-Induced migration and invasion of endometrial cancer cells[J]. Molecules, 21(8):1021-1029.
CHANG RJ, WANG CH, ZENG Q, et al., 2013. Chemical constituents of the stems of Celastrus rugosus[J]. Arch Pharm Res, 36(11):1291-1301.
CHEN SH, ZHAO PC, CHEN MZ, et al., 2017. Species identification and growth characteristics of endophytic anti-infective bacteria from herba Siegesbeckiae[J]. Biotechnol Bull, 33(2):137-142.[陳少紅, 趙朋超, 陳明釗, 等, 2017. 豨薟草內生抗感染細菌的分離鑒定及生長特性[J]. 生物技術通報, 33(2):137-142.]
CHEN DS, YU J, ZHANG L, 2016. Necroptosis:an alternative cell death program defending against cancer[J]. Biochimica et Biophysica Acta, 1865:228-236.
FANG QB, QIN KM, PAN Y, et al., 2010. Chemical composition of Baihe Zhimu decoction(I)[J]. Chin Trad Herb Drugs, 41(4):517-520.[方前波, 秦昆明, 潘揚, 等, 2010. 百合知母湯的化學成分研究(Ⅰ)[J]. 中草藥, 41(4): 517-520.]
FU XC, JIANG FP, FAN JZ, et al., 2013. Extract of herba Siegesbeckiae on mouse rheumatoid arthritis induced by anthrogen-CIA monoclonal antibody[J]. J Zhejiang Univ (Med Sci Ed), 42(5):556-560.[傅旭春, 蔣芳萍, 范珈禎, 等, 2013. 豨薟草對單克隆抗體組合誘導的小鼠類風濕關節(jié)炎作用[J]. 浙江大學學報醫(yī)學版, 42(5):556-560.]
HE W, CAO YL, 2016. The application of the addition and subtraction of Professor Zhao Jifus Chen Cao formula in apoplexy[J]. J Clin Med Lit, 3(17):3518-3519.[何威, 曹亞麗, 2016. 趙繼福教授豨薟草方加減在中風病中的應用[J]. 臨床醫(yī)藥文獻電子雜志, 3(17):3518-3519.]
HOFFMANN B,HLZL J, 1988. New Chalcones from Bidenspilosa[J]. Planta Med, 54:52-54.
HONG YH, WENG LW, CHANG CC, et al., 2014. Anti-inflammatory effects of Siegesbeckia orientalis ethanol extract in vitro and in vivo models[J]. Biol Med Res Int, (2):329712-329721.
KIM H, JEONG C, LIM E, et al., 2016. Antibacterial Effect of Siegesbeckia pubescens extract against fish pathogenic Streptococcus iniae[J]. Korean J Fish Aquat Sci, 49(5):678-682.
KWON JW, BYUN E, LEE EJ, et al., 2009. Antioxidative and hepatoprotective effect of compounds from the flowers of Bidens bipinnata L.[J]. Korean J Pharmacognosy, 40(4):345-350.
LAI-KING SY, GEOFFREY DB, 1998. Novel phenylpropanoids and lignans from Illicium verum[J]. J Nat Prod, 61(8):987-992.
LEE HJ, WU Q, LI H, et al., 2016. A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells[J]. Oncol Leet, 12(4):2912-2917.
LEE HN, JOO JH, OH JS, et al., 2014. Regulatory effects of Siegesbeckia glabrescens on non-small cell lung cancer cell proliferation and invasion[J]. Am J Chin Med, 42(2):453-463.
LI XL, WANG H, LIU G, et al., 2007. Study on chemical constituents from Desmodium styracifolium[J]. Chin Med Mat, 30(7):802-805.[李曉亮, 汪豪, 劉戈, 等, 2007. 廣金錢草的化學成分研究[J]. 中藥材, 30(7):802-805.]
LIU C, LI Z, LIANG Y, 2016. Research of compatibility law of traditional Chinese medicine in treating rheumatoid arthritis[C] // Biotechnology and Medical Science:Proceedings of the 2016 International Conference on Biotechnology and Medical Science. World Scientific:307-313.
LIU L, 2016. 46 cases of rheumatoid arthritis treated by oral medicine and rubbing[J]. Nei Mongol J Trad Chin Med, 35(4): 15-16.[劉流, 2016. 中湯藥內服與外擦治療類風濕關節(jié)炎46例[J]. 內蒙古中醫(yī)藥, 35(4):15-16.]
LOU YF, LI Y, HU B, 2013. Protective effect of total flavonoids in herba Siegesbeckiae on cerebral is chemia in rats[J]. J Pharm Pract, 31(1):42-44.[婁月芬, 李盈, 胡濱, 2013. 豨薟草總黃酮對大鼠腦缺血損傷的保護作用及其作用機制研究[J]. 藥學實踐雜志, 31(1):42-44.]
LU Y, QIAN RQ, XIAO J, et al., 2014. Kirenol, a compound from herba Siegesbeckiae, induces apoptosis in human chronic myeloid leukemia K562 cells[J]. Pharmazie, 69(2): 148.
LU YQ, QIU T, QIU CL, 2016. Qiu Changlins commonly used drugs for trigeminal neuralgia[J]. Chin J Trad Chin Med Pharm, 31(2):527-529.[盧裕強, 裘濤, 裘昌林, 2016. 裘昌林治療三叉神經(jīng)痛常用藥對采擷[J]. 中華中醫(yī)藥雜志, 31(2):527-529.]
NationalPharmacopoeia Commission, 2015. Pharmacopoeia of the Peoples Republic of China. A[M]. Beijing:China Medical Science Press:368.[國家藥典委員會, 2015. 中華人民共和國藥典. 一部[M]. 北京:中國醫(yī)藥科技出版社:368.]
NGUYEN TD, THUONG PT, HWANG IH, et al., 2017. Anti-Hyperuricemic, anti-inflammatory and analgesic effects of Siegesbeckia orientalis L. resulting from the fraction with high phenolic content[J]. BMC Compl Altern Med, 17(1):191-191.
PARK JA, JIN KS, JI YL, et al., 2013. Anti-oxidative and anti-obesity activities of Tetrapanax papyriferus and Siegesbeckia pubescens extracts and their synergistic anti-obesity effects[J]. J Biochem (Korean), 41(41):341-349.
SHEN Z, CAO Q, LIU XD, 2013. Effect of artemisia anomala, glandularstalk st. paulswort herb and tauro ursodesoxy cholic acid on the treatment of viral cholestatic hepatitis[J]. Jilin J Trad Chin Med, 33(12):1229-1231.[沈震, 曹琴, 劉旭東, 2013. 豨薟草聯(lián)合?;切苋パ跄懰嶂委煵《拘杂倌懶透窝譡J]. 吉林中醫(yī)藥, 33(12):1229-1231.]
SHI BH, JIA JW, WANG J, 2015. A clinical analysis of patients with hepatitis B virus related acute-on-chronic liver failure treated by combination of traditional Chinese and western medicine[J]. Chin J TCM WM Crit Care, 3(17):3518.[石斌豪, 賈建偉, 王嬌, 2015. 中西醫(yī)結合治療乙型肝炎病毒相關慢加急性肝衰竭患者的臨床療效分析[J]. 中國中西醫(yī)結合急救雜志, 22(3):267-271.]
WANG FH, FENG QX, YU B, et al., 2012. Siegesbeckia pubescens makino IIA on deep venous thrombosis of rat vWF and ICAM-1 Levels[J]. J Liaoning Univ Trad Chin Med,14(2):69-71.[王發(fā)輝, 馮起校, 于斌, 等, 2012. 腺梗豨薟IIA對深靜脈血栓形成大鼠vWF及ICAM-1水平的影響[J]. 遼寧中醫(yī)藥大學學報, 14(2):69-71.]
WANG YZ, LI GQ, 2016. Treatment of gout[J]. Chinas Naturopathy, 24(3):89-89.[王遠征, 李國慶, 2016. 治療痛風驗方[J]. 中國民間療法, 24(3):89-89.]
WEBER C, FRAEMOHS L, DEJANA E, 2007. The role of junctional adhesion molecules in vascular inflammation[J]. Nat Rev Immunol, 7(6):467-477.
WU J, QU Y, DENG JX, et al., 2017. Molecular docking studies of kirenol a traditional Chinese medicinal compound against rheumatoid arthritis cytokine drug targets (TNF-α, IL-1 and IL-6)[J]. Bio Med Res Int, 28(5):1992-1995.
WU LC, XIE NN, ZHOU SA, et al., 2016. The molecular mechanisms of necroptosis and its role in inflammation[J]. Chin J Cell Biol, 38(1):7-16.[吳晨露, 謝南南, 周伸奧, 等, 2016. 程序性細胞壞死的分子機制及其在炎癥中的作用[J]. 中國細胞生物學學報, 38(1):7-16.]
WU Q, LI H, LEE SY, et al., 2015. New cytotoxic sesquiterpenoids from Siegesbeckia glabrescens[J]. Molecules, 20(2): 2850-2856.
XIONG J, MA Y, XU YL, 1997. The constituents of Siegesbeckia orientalis[J]. Nat Prod Rep, 3 (1):14-18.
YANG Y, CHEN H, LEI JC, et al., 2016. Biological activity of extracts and active compounds isolated from Siegesbeckia orientalis L.[J]. Ind Crop Prod, 94:288-293.
YANG Q, YE G, 2009. A new C-glucoside from Commelina communis[J]. Chem Nat Compd, 45 (1):59-60.
ZENG LF, XU JW, XU L, et al., 2017. Separation and identification of flavonoids from Siegesbeckia glabrescens[J]. Chin J Exp Trad Med Form, 23(14):74-77.[曾令峰, 徐駿偉, 徐麗, 等, 2017. 毛梗豨薟草黃酮類化學成分分離鑒定[J]. 中國實驗方劑學雜志, 23(14):74-77.]
ZHANG C, CAI SJ, CHEN WY, et al., 2014. Scavenging effect of Siegesbeckia leaves extracts on hydroxyl radical[J]. J Southern Agric, 45(6):1060-1064.
ZHONG JD, LI YP, LI HM, et al., 2013. Chemical constituents from Croton caudatus var. tomentosus[J]. Nat Prod Res Dev, 25(12):1658-1661.[鐘金棟, 李艷平, 李洪梅, 等, 2013. 毛葉巴豆的化學成分研究[J]. 天然產物研究與開發(fā), 25(12):1658-1661.]
ZHU LL, XU L, LIU CL, et al., 2018. Advances in research of phytopharmaceutical effects of jacksonin recent five years[J]. Jiangxi J Trad Chin Med, 49(10):73-76.[朱伶俐, 徐麗, 劉春玲, 等, 2018. 近五年豨薟草藥理作用研究進展[J]. 江西中醫(yī)藥, 49(10):73-76.]
ZHU LL, XU L, WU HQ, et al., 2018. Chemical components of Siegesbeckia glabrescensⅡ[J]. Chin J Exp Trad Med Form, 24(2):57-61.[朱伶俐, 徐麗, 吳華強, 等, 2018. 毛梗豨薟草化學成分研究Ⅱ[J]. 中國實驗方劑學雜志, 24(2):?57-61.]
(責任編輯?蔣巧媛)